10-Q: Outlook Therapeutics Reports Q1 2024 Results, Outlines Path Forward for ONS-5010

Outlook Therapeutics reported its financial results for the quarter ended December 31, 2023, and provided updates on its clinical and regulatory progress for ONS-5010.

Summary

• Outlook Therapeutics reported a net loss of $11.2 million for the three months ended December 31, 2023, compared to a net loss of $18.7 million for the same period in 2022.
• Research and development expenses decreased to $4.5 million from $9.9 million year-over-year, primarily due to reduced ONS-5010 development costs after receiving a Complete Response Letter (CRL) from the FDA.
• General and administrative expenses remained relatively stable at $5.8 million.
• The company's cash and cash equivalents stood at $10.4 million as of December 31, 2023.
• Outlook Therapeutics is pursuing a private placement to raise up to $65 million in gross proceeds, with potential for an additional $99 million upon warrant exercises.
• The company has also amended its December 2022 note to extend the maturity to July 1, 2025, subject to certain conditions.
• A new clinical trial, NORSE EIGHT, has been initiated to address the FDA's requirement for a second adequate and well-controlled clinical trial for ONS-5010.
• The company expects topline results from NORSE EIGHT and a potential BLA resubmission by the end of calendar year 2024.
• The European Medicines Agency (EMA) is reviewing the Marketing Authorization Application (MAA) for ONS-5010, with a decision expected in the first half of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the initiation of NORSE EIGHT and the potential capital raise, the company's financial situation is precarious, and the FDA's CRL is a significant setback. The company's future is highly dependent on the successful completion of the private placements and the NORSE EIGHT trial.

Positives

• The company's net loss decreased significantly year-over-year.
• Research and development expenses were reduced, reflecting a more focused approach.
• The company has initiated the NORSE EIGHT trial, addressing a key FDA requirement.
• The company has secured a potential capital raise of up to $164 million.
• The maturity of the December 2022 note has been extended, providing more financial flexibility.
• The EMA review of the MAA is underway, with a decision expected soon.

Negatives

• The company continues to operate at a loss and has an accumulated deficit of $479 million.
• The company's cash reserves are limited, with $10.4 million on hand as of December 31, 2023.
• The company is dependent on the successful completion of the private placement and warrant exercises to fund operations.
• The company is subject to a securities class action lawsuit.
• The company's ability to continue as a going concern is dependent on the success of the private placements and the note amendment.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The private placements and note amendment are subject to closing conditions, including stockholder approval.
• The company is subject to a securities class action lawsuit, which could result in significant costs.
• The company's success is dependent on the successful completion of clinical trials and regulatory approvals.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company's financial results may be impacted by macroeconomic factors, including inflation and interest rates.
• There is no guarantee that the company will be able to successfully commercialize ONS-5010.

Future Outlook

The company expects topline results from the NORSE EIGHT trial and a potential BLA resubmission by the end of calendar year 2024. The EMA is expected to make a decision on the MAA for ONS-5010 in the first half of 2024. The company believes that its existing cash and cash equivalents, combined with the expected proceeds from the private placements, are sufficient to support operations through June 2025.

Management Comments

• Management believes that the existing cash and cash equivalents, combined with the expected proceeds from the Private Placements, are sufficient to support operations, complete the execution of NORSE EIGHT, resubmit the ONS-5010 BLA and, if approved, support the commercial launch of ONS-5010.
• Management is currently evaluating various strategic opportunities to obtain the required funding for future operations.

Industry Context

The company is developing ONS-5010 as an ophthalmic formulation of bevacizumab for retinal indications, aiming to be the first approved product of its kind in the US. This addresses the current off-label use of repackaged bevacizumab, which accounts for a significant portion of new patient starts. The company is also seeking approval in Europe, Japan, and other markets.

Comparison to Industry Standards

• The company's clinical trial results for ONS-5010 in wet AMD, particularly the NORSE TWO trial, showed statistically significant and clinically relevant improvements in visual acuity compared to ranibizumab (LUCENTIS).
• The company is pursuing a standard BLA pathway, rather than a biosimilar pathway, as there are no approved bevacizumab products for retinal diseases in the US, which is different from companies developing biosimilars of existing drugs.
• The company's approach to addressing the FDA's concerns through the NORSE EIGHT trial and CMC resolution is consistent with industry practices for regulatory submissions.
• The company's financial situation is typical of a clinical-stage biopharmaceutical company, with significant losses and reliance on external funding.

Management Changes

Legal Proceedings

• A securities class action lawsuit was filed against the company and certain of its officers on November 3, 2023, alleging violations of the Securities Exchange Act of 1934 related to statements made about the company's BLA.

Related Party Transactions

• The company has a joint venture agreement with Syntone PRC, which owns 80% of Beijing Syntone Biopharma Ltd, with Outlook owning 20%.
• The company entered into a royalty-free license with Syntone JV for the development, commercialization and manufacture of ONS-5010 in the greater China market.
• The company had a strategic partnership agreement with MTTR, which was terminated in 2020, and subsequently entered into consulting agreements with the principals of MTTR.

Stakeholder Impact

• Shareholders face the risk of dilution from the private placements and potential losses from the securities class action lawsuit.
• Employees may be affected by potential workforce reductions if the company is unable to secure sufficient funding.
• Customers (ophthalmologists and patients) are awaiting the potential approval of ONS-5010 as a new treatment option.
• Suppliers and creditors are exposed to the risk of non-payment if the company's financial situation deteriorates.
• The company's ability to continue as a going concern is dependent on the success of the private placements and the note amendment.

Next Steps

• Complete the NORSE EIGHT clinical trial.
• Resubmit the BLA for ONS-5010 to the FDA.
• Obtain a decision on the MAA for ONS-5010 from the EMA.
• Secure stockholder approval for the private placements and note amendment.
• Close the private placements and receive the associated funding.
• Prepare for the potential commercial launch of ONS-5010.

Key Dates

Keywords

ONS-5010, LYTENAVA, wet AMD, retinal diseases, clinical trials, FDA, EMA, biopharmaceutical, private placement, capital raise, NORSE EIGHT, MAA, BLA